Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure used to replace damaged heart valves, ...

The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes.

international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. These patients had a predicted 30-day mortality risk 3%, as assessed by a local ...

1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve™ and 684 undergoing surgery. The term of the financing agreement is for three years ...

international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. These patients had a predicted 30-day mortality risk <3%, as assessed by a ...

Medtronic's recent regulatory approvals should bode well for non-GAAP EPS growth in the coming years. Read why I am ...

“I do not think that the data in this comparative head-to-head TAVR trial is really encouraging to use Myval ... “Here you actually have a valve that can compete with both Evolut and Sapien, so why ...